Why Immix Biopharma, Inc.’s (IMMX) Stock Is Up 7.18%
As of Tuesday, October 20, Immix Biopharma, Inc.’s IMMX share price has surged by 7.18%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Commentary & Analysis
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Down 6.22%
As of Friday, October 16, Immix Biopharma, Inc.’s IMMX share price has dipped by 6.22%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Down 5.18%
As of Tuesday, October 06, Immix Biopharma, Inc.’s IMMX share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Down 5.97%
As of Tuesday, September 29, Immix Biopharma, Inc.’s IMMX share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Michael Rose
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Down 10.11%
As of Tuesday, September 29, Immix Biopharma, Inc.’s IMMX share price has dipped by 10.11%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $738.7 | $228.4 | 42% |
|
| Shares Out (Mil) | 63.8 | 53.9 | 53% |
|
| Institutional Ownership | 88.7% | 92.9% | 56% |
|
| Float (Mil) | 67.5 | 41.7 | 53% |
|
| Beta | 0.11 | 0.95 | 9% |
|
| Avg Daily Volume (000s) | 1,290 | 582 | 75% |
|
| Price Change (52-week) |
210.5% | 47.6% | 99% |
|
| Growth | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (92.9%) | (10.1%) | 2% |
|
| EPS (5yr) | (21.3%) | 15.8% | 12 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 90.5% | (15.7%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($0.186) | ($0.721) | ($0.948) | |
| Month Ago EPS | ($0.189) | ($0.720) | ($0.856) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.172) | ($0.691) | ($0.742) | |
| Year/Year Chg | 2.8% | (19.3%) | (25.8%) | |
| Financials | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($40) | ($44) | 18% |
|
| EPS (TTM) | ($0.834) | ($1.500) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $214 | $2 | 85% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $464 | $177 | 33% |
|
| Valuation | IMMX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.78 | 2.19 | 65% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (31.3%) | (47.1%) | 16% |
|
| ROE | (34.2%) | (54.1%) | 19% |
|
| Liabilities to Assets | 4.3% | 29.1% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Immix Biopharma, Inc. did not pass any screens on 10/20/2026.
